Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

474 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer.
Lahn M, McClelland P, Ballard D, Mintze K, Thornton D, Sandusky G. Lahn M, et al. Among authors: thornton d. Histopathology. 2006 Oct;49(4):429-31. doi: 10.1111/j.1365-2559.2006.02461.x. Histopathology. 2006. PMID: 16978209 No abstract available.
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA. Edelman MJ, et al. Among authors: thornton d. Lung Cancer. 2003 Feb;39(2):197-9. doi: 10.1016/s0169-5002(02)00511-1. Lung Cancer. 2003. PMID: 12581573 Clinical Trial.
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Carducci MA, et al. Among authors: thornton de. J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.
Although no MTD was identified up to 700 mg/d, 525 mg was chosen as the recommended dose, and 12 additional patients were accrued at that level. ...Enzastaurin is well tolerated up to 700 mg/d. Evidence of early activity was seen with significant stable disease....
Although no MTD was identified up to 700 mg/d, 525 mg was chosen as the recommended dose, and 12 additional patients were accrued at …
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Crump M, Leppä S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T. Crump M, et al. Among authors: thornton d. J Clin Oncol. 2016 Jul 20;34(21):2484-92. doi: 10.1200/JCO.2015.65.7171. Epub 2016 May 23. J Clin Oncol. 2016. PMID: 27217449 Clinical Trial.
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.
Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ Sr. Miller KD, et al. Among authors: thornton d. Ann Oncol. 2000 Jan;11(1):101-3. doi: 10.1023/a:1008305205159. Ann Oncol. 2000. PMID: 10690396 Clinical Trial.
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D. Eisenberger MA, et al. Among authors: thornton d. Urology. 2004 Jan;63(1):114-9. doi: 10.1016/j.urology.2003.08.017. Urology. 2004. PMID: 14751361 Clinical Trial.
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
Nwankwo N, Zhang Z, Wang T, Collins C, Resta L, Ermisch S, Day J, Decker R, Kornberg L, Nicol S, Thornton D, Armstrong DK, Carducci MA. Nwankwo N, et al. Among authors: thornton d. Invest New Drugs. 2013 Jun;31(3):653-60. doi: 10.1007/s10637-012-9850-6. Epub 2012 Jul 6. Invest New Drugs. 2013. PMID: 22766773 Free PMC article. Clinical Trial.
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.
Galsky MD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S, Stille JR, Saleh M, Thornton D. Galsky MD, et al. Among authors: thornton d. Clin Cancer Res. 2014 Jul 1;20(13):3581-8. doi: 10.1158/1078-0432.CCR-13-2686. Epub 2014 Apr 11. Clin Cancer Res. 2014. PMID: 24727324 Clinical Trial.
A phase I trial of enzastaurin in patients with recurrent gliomas.
Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA. Kreisl TN, et al. Among authors: thornton d. Clin Cancer Res. 2009 May 15;15(10):3617-23. doi: 10.1158/1078-0432.CCR-08-3071. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417015 Free PMC article. Clinical Trial.
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. Camidge DR, et al. Among authors: thornton d. Anticancer Drugs. 2008 Jan;19(1):77-84. doi: 10.1097/CAD.0b013e3282f077b3. Anticancer Drugs. 2008. PMID: 18043132 Clinical Trial.
In subsequent 21-day cycles, enzastaurin was given orally, once daily, on days 1-21 and capecitabine orally, twice daily (b.i.d.), on days 1-14 in three dose-level cohorts. Three dose-escalation cohorts were studied: cohort 1 (n=8), 350 mg of enzastaurin +capecitabine (750 …
In subsequent 21-day cycles, enzastaurin was given orally, once daily, on days 1-21 and capecitabine orally, twice daily (b.i.d.), on …
474 results
Jump to page
Feedback